Truist maintains Buy on Collegium Pharmaceutical; cuts price target to $49
Truist Securities maintained a Buy on Collegium Pharmaceutical and cut its price target to $49.00 per share from $58.00, per Benzinga/TradingView.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.